Celldex Announces $300 Million Public Stock Offering

Biotech firm plans to use proceeds for commercial launch, R&D, and general corporate purposes.

Apr. 2, 2026 at 2:37am

Got story updates? Submit your updates here. ›

Celldex Therapeutics, Inc. announced the pricing of a $300 million underwritten public offering of 10,345,000 shares of its common stock at $29.00 per share. The company also granted underwriters a 30-day option to purchase up to an additional 1,551,750 shares. Celldex intends to use the net proceeds to fund commercial readiness activities, continue clinical development of its product candidates, grow its bispecific antibody platform, and for general corporate purposes.

Why it matters

This public offering will provide Celldex with significant capital to advance its pipeline of antibody-based therapeutics targeting severe inflammatory, allergic, and autoimmune diseases. The funds will support the potential commercial launch of the company's lead candidate barzolvolimab for chronic spontaneous urticaria, if approved, as well as continued research and development efforts.

The details

Celldex plans to use the proceeds from the $300 million offering, along with its existing cash, to fund ongoing commercial readiness activities and the potential launch of barzolvolimab, continue clinical and preclinical development of its product candidates, grow its bispecific antibody platform, and for general corporate purposes. The offering is expected to close on or about April 6, 2026, subject to customary closing conditions.

  • The public offering was priced on April 1, 2026.
  • The offering is expected to close on or about April 6, 2026.

The players

Celldex Therapeutics, Inc.

A clinical-stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients.

Leerink Partners

One of the joint bookrunning managers for the Celldex public offering.

TD Cowen

One of the joint bookrunning managers for the Celldex public offering.

Guggenheim Securities

One of the joint bookrunning managers for the Celldex public offering.

Cantor

One of the joint bookrunning managers for the Celldex public offering.

Got photos? Submit your photos here. ›

What’s next

The offering is expected to close on or about April 6, 2026, subject to customary closing conditions.

The takeaway

Celldex's $300 million public stock offering will bolster the company's financial resources to support the potential commercial launch of its lead drug candidate, continue R&D efforts, and further develop its bispecific antibody platform as it aims to bring transformative therapies to patients with severe inflammatory, allergic, and autoimmune diseases.